Hrisimir Kostov

Hrisimir Kostov

Auto-generated profile, based on publicly available information

Hrisimir Kostov

National Center for Epilepsy, University Hospital, member of the European Reference Network EpiCARE, P.O. Box 4950 Nydalen, 0424 Oslo, Norway

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2021 in Epilepsia
Verified
Journal Article
Open access
PDF file
KKKonstantin H. Kostov
Konstantin H. Kostov
HKHrisimir Kostov
Hrisimir Kostov
PLPål Gunnar Larsson
Pål Gunnar Larsson
OHOliver Henning
Oliver Henning
CEChristian Alexander Cornelius Eckmann
Christian Alexander Cornelius Eckmann
JPJukka Peltola
Jukka Peltola
Objective: This study was undertaken to evaluate the efficacy of vagus nerve stimulation (VNS) over time, and to determine which patient groups derive the most benefit.Methods: Long‐term outcomes are reported in 436 epilepsy patients from a VNS quality registry (52.8% adults, 47.2% children), with a median follow‐up of 75 months. Patients were stratified according to evolution of response into constant responders, fluctuating responders, and nonresponders. The effect was evaluated at 6, 12, 24, 36, and 60 months. Multivariate regression analysis was used to identify predictors of response.Results: The cumulative probability of ≥50% seizure reduction was 60%; however, 15% of patients showed a fluctuating course. Of those becoming responders, 89.5% (230/257) did so within 2 years. A steady increase in effect was observed among constant responders, with 48.7% (19/39) of those becoming seizure‐free and 29.3% (39/133) with ≥75% seizure reduction achieving these effects within 2–5 years. Some effect (25%–<50%) at 6 months was a positive predictor of becoming a responder (odds ratio [OR] = 10.18, p < .0001) and having ≥75% reduction at 2 years (OR = 3.34, p = .03). Patients without intellectual disability had ORs of 3.34 and 3.11 of having ≥75% reduction at 2 and 5 years, respectively, and an OR of 6.22 of being seizure‐free at last observation. Patients with unchanged antiseizure medication over the observation period showed better responder rates at 2 (63.0% vs. 43.1%, p = .002) and 5 years (63.4% vs. 46.3%, p = .031) than patients whose antiseizure medication was modified. Responder rates were higher for posttraumatic (70.6%, p = .048) and poststroke epilepsies (75.0%, p = .05) than other etiologies (46.5%).Significance: Our data indicate that the effect of VNS increases over time and that there are important clinical decision points at 6 and 24 months for evaluating and adjusting the treatment. There should be better selection of candidates, as certain patient groups and epilepsy etiologies respond more favorably.

1 February 2015 in Pediatric Neurology
Verified
Journal Article
Closed access
CLCaroline Lund
Caroline Lund
MBMarit Bjørnvold
Marit Bjørnvold
MTMia Tuft
Mia Tuft
HKHrisimir Kostov
Hrisimir Kostov
OROddveig Røsby
Oddveig Røsby
KSKaja Kristine Selmer
Kaja Kristine Selmer

6 February 2024 in Epilepsia Open
Verified
Journal Article
Open access
KKKonstantin H. Kostov
Konstantin H. Kostov
HKHrisimir Kostov
Hrisimir Kostov
PLPål Gunnar Larsson
Pål Gunnar Larsson
OHOliver Henning
Oliver Henning
KAKari Modalsli Aaberg
Kari Modalsli Aaberg
MLMorten Ingvar Lossius
Morten Ingvar Lossius
Objective: Evaluate the long‐term efficacy of vagus nerve stimulation (VNS) in patients with developmental and epileptic encephalopathies (DEE) compared with epilepsy patients without intellectual disability (ID).Methods: Long‐term outcomes from a Norwegian VNS quality registry are reported in 105 patients with DEEs (Lennox–Gastaut syndrome [LGS] n = 62; Dravet n = 16; Rett n = 9; other syndromes n = 18) were compared with 212 epilepsy patients without ID, with median follow‐up of 88 and 72 months, respectively. Total seizure reduction was evaluated at 6, 12, 24, 36, and 60 months. Effect on different seizure types was evaluated at baseline and last observation carried forward (LOCF).Results: Median monthly seizure frequency at LOCF was reduced by 42.2% (p < 0.001) in patients with DEE and by 55.8% (p < 0.001) in patients without ID. In DEE patients, ≥50% seizure reduction at 6 and 24 months were 17.1% and 37.1%, respectively, and 33.5% and 48.6% for patients without ID. Seizure reduction ≥75% at 60 months occurred in 14.3% of DEE patients and 23.1% of patients without ID. Highest median reduction was for atonic seizures, most notably 64.6% for LGS patients. A better effect was seen at 2 years among DEE patients with unchanged medication compared with those with changed medication (54.5% vs. 35.6% responders, p = 0.078). More DEE patients were reported to have greater improvement in ictal or postictal severity (43.8% vs. 28.3%, p = 0.006) and alertness (62.9% vs. 31.6%, p < 0.001) than patients without ID. For both groups, use of the magnet reduced seizure severity. Hoarseness was the most common adverse effect in both groups. In addition, DEE patients were frequently reported to have sleep disturbance, general discomfort, or abdominal problems.Significance: Our data indicate that VNS is very effective for atonic seizures. Patients without ID had best overall seizure reduction, however, patients with DEE had higher retention rates probably due to other positive effects.Plain Language Summary: DEE refers to a group of patients with severe epilepsy and intellectual disability. Many of these patients have restricted lifestyles with frequent seizures. VNS is a treatment option for patients who do not respond well to medicines, either because of insufficient effect or serious adverse effects. Our study shows that VNS is well tolerated in this patient group and leads to a reduction in all seizure types, most notably for seizures leading to fall. Many patients experience other positive effects like shorter and milder seizures, as well as improvement in alertness.

1 July 2025 in Brain Stimulation
Verified
Journal Article
Open access
KKKonstantin Hrisimirov Kostov
Konstantin Hrisimirov Kostov
HKHrisimir Kostov
Hrisimir Kostov
PLPål Gunnar Larsson
Pål Gunnar Larsson
OHOliver Henning
Oliver Henning
AEArild Egge
Arild Egge
JPJukka Peltola
Jukka Peltola
Despite widespread use of vagus nerve stimulation (VNS), evidence regarding optimal stimulation titration and dosing remains limited. Significant inter-practice variability and deviation from guidelines, results in sub-optimal dosing. Identify optimal stimulation parameters and establish target dosing for VNS therapy in epilepsy. We linked long-term outcomes with dosing parameters in 415 patients from a VNS registry (median follow-up=79.0 months). A generalized linear mixed model (GLMM) assessed relationships between stimulation parameters (Output Current (OC), Frequency, Pulse Width (PW), Duty cycle (DC)) and very good clinical response (≥75% seizure frequency reduction from baseline). Output current was the strongest predictor of seizure reduction (p=0.001). Increasing OC by 1mA more than doubled the probability of ≥75% seizure reduction, peaking at 2.70mA. Greatest likelihood of ≥50% seizure reduction was at 2.1mA. Post-hoc analysis supported GLMM findings, showing significantly more patients (46.3%) receiving >2.0mA OC achieved ≥75% seizure reduction compared with 30.7% (p=0.01) among patients using lower OC. Although changes in DC were not significantly associated with seizure reduction, post-hoc analysis suggested benefits from other duty cycles. Standard 250μs PW and 20Hz frequency were associated with best effect. Longer follow-up improved seizure control (p<0.001); intellectual disability negatively impacted response (p=0.005). Seizure-free patients had significantly lower total charge (122.4 vs. 250.1mC, p=0.014) than patients with persistent seizures. Output current should be the primary focus when titrating VNS patients to optimal dose. We suggest a target range of 1.5 - 2.25mA with 250μs PW and 20Hz frequency. Higher OC should be attempted if tolerated.

13 August 2025 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Open access
OHOliver Henning
Oliver Henning
NANoemi Becser Andersen
Noemi Becser Andersen
FAFredrik Asztely
Fredrik Asztely
EBElinor Ben-Menachem
Elinor Ben-Menachem
HGHelena Gauffin
Helena Gauffin
JPJukka Peltola
Jukka Peltola
Despite VNS therapy being established broadly as a second line treatment for drug resistant epilepsy, there are currently no guidelines or recommendations giving sufficient and detailed guidance and suggestions to fully utilize the increasing array of parameter options. A panel of 22 experts from the Nordic countries (6 were pediatric neurologists, 14 neurologists and 2 treating both pediatric and adult patients) was assembled to share their experience with VNS therapy using a 5-step Delphi approach. Agreement level ≥80% was considered strong consensus and 60 to79% was considered medium consensus. After the third round of the Delphi process there were 70 statements in different sections as: How to start the VNS after implantation (9 statements), How to do further adjustment after the initial phase (13 statements), How to use Autostimulation mode (14 statements), How to use scheduled programming (8 statements), Are there special settings for special seizure types/diagnosis (6 statements), How to use day-night programming (3 statements), What to know about Magnet mode (6 statements), How to manage side effects (3 statements), Considerations about gender/age and patient preferences (4 statements), and Practical programming (4 statements). In 46 statements (65.7%) the panel reached a strong consensus, in 11 (17.7%) a medium consensus, and in 13 (18.6%) no consensus was achieved. The recommendations of the Delphi panel emphasize proactive deployment of available stimulation options including build up in duty cycle and the use of rapid cycling as well as increasing the output current if response with primary target current is insufficient. Additionally, the usage of Magnet mode and Autostimulation mode were encouraged. Guidance on how to use the newest stimulation options such as day-and-night and scheduled programming for improved feasibility and tolerability is provided.

1 January 2021 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
KKKonstantin Hrisimirov Kostov
Konstantin Hrisimirov Kostov
HKHrisimir Kostadinov Kostov
Hrisimir Kostadinov Kostov
PLPål Gunnar Larsson
Pål Gunnar Larsson
OHOliver Henning
Oliver Henning
CEChristian Alexander Cornelius Eckmann
Christian Alexander Cornelius Eckmann
JPJukka Peltola
Jukka Peltola
Background: Vagus nerve stimulation (VNS) is used for patients with drug-resistant epilepsy not amenable to epilepsy surgery. However, the efficacy of VNS treatment over time, and which patients with which etiologies derive most benefit from VNS, is uncertain. Methods: We report long-term outcomes of VNS in 436 epilepsy patients (52·8% adults, 47·2% children), with median follow-up of 75 months (six to 254). Patients were stratified into constant responders, fluctuating responders, and non-responders. We used regression analysis to identify predictors of response. Findings: The cumulative probability of ≥50% seizure reduction was 60%, however 15% of patients showed a fluctuating course. Of those becoming responders, 89·5% (230/257) did so within two years. A steady increase in effect was observed among constant responders, with 48·7% (19/39) of those becoming seizure-free, and 29·3% (39/133) with ≥75% seizure reduction achieving these effects within between two and five years. Some effect (<50%) at six months was a positive predictor of becoming a responder (OR=10·18, CI 5·50–18·87, p<0·0001) and having ≥75% reduction at two years (OR=3·34, CI 1·50-7·45, p=0.03). Patients without intellectual disability had OR of 3·34 and 3·11 of having ≥75% reduction at two and five years, respectively. Among these patients, the OR of being seizure-free at last control of follow-up was 6·22. Patients with unchanged anti-seizure medication over observation period showed better responder rates at two years (63·0% vs. 43·1%, p=0·002) and five years (63·4% vs. 46·3%, p= 0·031) than patients whose anti-seizure medication was modified. Responder rates were higher for post-traumatic (70·6%, p=0·048) and post-stroke epilepsies (75·0%, p=0·05) than other etiologies (46·5%). Interpretation VNS is a viable treatment option for refractory epilepsy. Our data provide information about effects over time and for different patient groups and epilepsy etiologies. Funding Information: This work was done at and internally funded by the National Center for Epilepsy in Sandvika, Norway. Declaration of Interests: Dr. Peltola reports grants, personal fees and other from Eisai, grants, personal fees and other from UCB, grants, personal fees and other from Livanova, grants, personal fees and other from Medtronic, other from Bial, personal fees and other from Orion Pharma, other from Arvelle, other from Novartis, other from Phizer, outside the submitted work; all other authors have nothing to disclose. Ethics Approval Statement: The study was approved by the Regional Committee for Medical and Health Research Ethics (REK; ref. number 2018/2183) and the Norwegian Centre for Research Data (Personvernombud; ref. number 18/19827).